Mauna Kea Technologies: New Cellvizio Order Placed by UGAP for Rouen University Hospital

PARIS, June 30,2016 /PRNewswire/ --

Second Cellvizio order by France's largest hospital purchasing group (UGAP)
Paris, France and Cambridge, MA, USA, June 30, 2016 - Mauna Kea Technologies (Euronext : MKEA, FR0010609263, OTCQX: MKEAY), inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, announced that is has received today a second order for a Cellvizio endomicroscopy system from Union des Groupements d'Achat Public (UGAP), France's largest hospital purchasing group. This order is for the University Hospital of Rouen and follows UGAP's initial Cellvizio system purchase for the Avignon Hospital Center, which occurred in late March shortly after Mauna Kea won the "Innovations" competitive bidding launched by UGAP in November 2015.
"We are pleased to see good momentum in France thanks to our partnership with UGAP, with a second Cellvizio order placed this year We continue to work hard in order for French patients to be able to benefit from the same care opportunities than American patients, in spite of French public authorities' failure to address the issue. The Rouen University Hospital is well known for its excellence in the treatment of GI diseases, and its patients will now further benefit from Cellvizio which may save both patients and the healthcare system from costly and potentially morbid repeat procedures" declared Sacha Loiseau, Ph.D., Co-Founder and CEO of Mauna Kea Technologies.

About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer thanks to real time in vivo microscopic visualization. The Company's flagship product, Cellvizio, has received clearance to sell a wide range of applications in more than 40 countries, including the United States, Europe, Japan, China, Canada, Brazil and Mexico. For more information on Mauna Kea Technologies, visit www.maunakeatech.com

Disclaimer
This press release contains forward-looking statements concerning Mauna Kea Technologies and its activities. Such forward-looking statements are based on assumptions that Mauna Kea Technologies considers to be reasonable. However, there can be no assurance that the anticipated events contained in such forward-looking statements will occur. Forward-looking statements are subject to numerous risks and uncertainties including the risks set forth in the registration document of Mauna Kea Technologies registered by the French Financial Markets Authority (Autorité des marchés financiers (AMF)) on 24 June 2015 under number R.15-056 and available on the Company's website (www.maunakeatech.com), and to the development of economic situation, financial markets, and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this release are also subject to risks unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not consider material at this time. The realization of all or part of these risks could lead to actual results, financial conditions, performances or achievements by Mauna Kea Technologies that differ significantly from the results, financial conditions, performances or achievements expressed in such forwardlooking statements. This press release and the information it contains do not constitute an offer to sell or to subscribe for, or a solicitation of an order to purchase or subscribe for, Mauna Kea Technologies shares in any country.

Mauna Kea Technologies
Benoit Jacheet
CFO
investors@maunakeatech.com

United States
Zack Kubow / Lee Roth
The Ruth Group
646-536-7020 / 7012
zkubow@theruthgroup.com 
lroth@theruthgroup.com

U.S. Media
Christopher Hippolyte
The Ruth Group
646-536-7023
chippolyte@theruthgroup.com

France and Europe
NewCap - Investor Relations
Florent Alba
+33 (0)1 44 71 94 94
maunakea@newcap.fr

This is a disclosure announcement from PR Newswire.

SOURCE Mauna Kea Technologies